At a glance
ClinicalIndex Comparison RecordN/ACompleted· 157 enrolled
Drug / intervention
T4020 +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking
In Brief
A clinical study evaluating T4020 and Placebo for Keratoconus. Completed, enrolled 157 participants across 4 sites in 4 countries.
Detailed Summary
The purpose of this study is to assess the performance and safety of T4020 versus saline solution.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKeratoconus
CountriesBulgaria, France, Spain, Turkey (Türkiye)
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartDec 2016
Primary CompletionMar 2018
TodayJul 2026
First PostedDec 1, 2016
Enrollment StartDec 1, 2016
Primary CompletionMar 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.6 years ago
Interventions
T4020device
Placebodevice